[go: up one dir, main page]

RU2003102437A - 7-гидроксиэпиандростерон, обладающий нейропротективной активностью - Google Patents

7-гидроксиэпиандростерон, обладающий нейропротективной активностью Download PDF

Info

Publication number
RU2003102437A
RU2003102437A RU2003102437/15A RU2003102437A RU2003102437A RU 2003102437 A RU2003102437 A RU 2003102437A RU 2003102437/15 A RU2003102437/15 A RU 2003102437/15A RU 2003102437 A RU2003102437 A RU 2003102437A RU 2003102437 A RU2003102437 A RU 2003102437A
Authority
RU
Russia
Prior art keywords
hydroxyepiandrosterone
use according
hydroxy
neuroprotective activity
epiandrosterone
Prior art date
Application number
RU2003102437/15A
Other languages
English (en)
Other versions
RU2307654C2 (ru
Inventor
Эшли Кер ПРИНГЛ (GB)
Эшли Кер ПРИНГЛ
Ларс Эрик САНДСТРОМ (GB)
Ларс Эрик САНДСТРОМ
Эрнст ВЮЛФЕРТ (BE)
Эрнст ВЮЛФЕРТ
Original Assignee
Хантэр-Флеминг Лимитед (Gb)
Хантэр-Флеминг Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хантэр-Флеминг Лимитед (Gb), Хантэр-Флеминг Лимитед filed Critical Хантэр-Флеминг Лимитед (Gb)
Publication of RU2003102437A publication Critical patent/RU2003102437A/ru
Application granted granted Critical
Publication of RU2307654C2 publication Critical patent/RU2307654C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (6)

1. Применение 7-гидроксиэпиандростерона для производства лекарственного препарата для защиты от острого или хронического нейронного повреждения.
2. Применение по п.1, при котором 7-гидрокси-эпиандростерон является 7б-гидроксиэпиандростероном.
3. Применение по п.1, при котором 7-гидрокси-эпиандростерон является 7в-гидроксиэпиандростероном.
4. Применение по п.1, при котором 7-гидрокси-эпиандростерон является смесью 7α-гидроксиэпиандростерона и 7β-гидроксиэпиандростерона.
5. Применение по любому из предществующих пунктов, при котором нейронное повреждение вызвано инсультом или травмой головного мозга.
6. Применение по любому предшествующему пункту, при котором нейронное повреждение вызвано болезнью Альцгеймера, болезнью Паркинсона, когнитивным нарушением без деменции, травмой спинного мозга или травмой периферического нерва.
RU2003102437/15A 2000-06-29 2001-06-29 7-гидроксиэпиандростерон, обладающий нейропротективной активностью RU2307654C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0016022A GB2363983A (en) 2000-06-29 2000-06-29 Protection against neuronal damage using 7-hydroxyepiandrosterone
GB0016022.6 2000-06-29
PCT/GB2001/002937 WO2002000225A1 (en) 2000-06-29 2001-06-29 7-hydroxyepiandrosterone having neuroprotective activity

Publications (2)

Publication Number Publication Date
RU2003102437A true RU2003102437A (ru) 2005-01-27
RU2307654C2 RU2307654C2 (ru) 2007-10-10

Family

ID=9894707

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003102437/15A RU2307654C2 (ru) 2000-06-29 2001-06-29 7-гидроксиэпиандростерон, обладающий нейропротективной активностью

Country Status (24)

Country Link
US (2) US7718639B2 (ru)
EP (1) EP1294382B1 (ru)
JP (1) JP4942905B2 (ru)
KR (1) KR100786284B1 (ru)
CN (1) CN100459980C (ru)
AT (1) ATE401897T1 (ru)
AU (2) AU2001267709B2 (ru)
CA (1) CA2414584C (ru)
CY (1) CY1108773T1 (ru)
CZ (1) CZ299676B6 (ru)
DE (1) DE60134979D1 (ru)
DK (1) DK1294382T3 (ru)
ES (1) ES2310182T3 (ru)
GB (1) GB2363983A (ru)
HK (1) HK1052300B (ru)
HU (1) HU227152B1 (ru)
IL (2) IL153541A0 (ru)
NO (1) NO327959B1 (ru)
PL (1) PL200699B1 (ru)
PT (1) PT1294382E (ru)
RU (1) RU2307654C2 (ru)
SI (1) SI1294382T1 (ru)
WO (1) WO2002000225A1 (ru)
ZA (1) ZA200300085B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2363984A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
GB2378898A (en) * 2001-08-14 2003-02-26 Hunter Fleming Ltd Prophylactic and therapeutic use of hydroxysteroids
US20040138187A1 (en) * 2002-08-28 2004-07-15 Reading Christopher L. Therapeutic treatment methods
GB0409498D0 (en) * 2004-04-28 2004-06-02 Hunter Fleming Ltd Transdermal steroid formulation
ES2662500T3 (es) 2006-11-21 2018-04-06 Asarina Pharma Ab El uso de esteroides de pregnano y androstano para la preparación de una composición farmacéutica para el tratamiento de trastornos del sistema nervioso central
CA2670957A1 (en) 2006-11-30 2008-06-05 Hunter-Fleming Limited Modulation of prostaglandin/cyclooxygenase metabolic pathways
GB0623971D0 (en) * 2006-11-30 2007-01-10 Hunter Fleming Ltd Modulation of prostaglandin/cyclooxygenase metabolic pathways

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU243975A (en) 1974-10-14 1982-06-30 Schering Ag Process for obtaining 7-hydroxyestradiols
US5707983A (en) * 1990-08-29 1998-01-13 Humanetics Corporation Treatment of alzheimer's disease and modulation of immune system with Δ5-androstenes
US5292730A (en) * 1990-08-29 1994-03-08 Humanetics Corporation Modulation of immune system with Δ5-androstenes
US5212167A (en) * 1991-09-12 1993-05-18 Trustees Of Boston University Modulation of receptor-mediated ion transport
FR2696934B1 (fr) * 1992-10-20 1995-06-02 Conservatoire Nal Arts Metiers Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir.
CZ193495A3 (en) 1993-03-09 1996-04-17 Univ Utah Res Found The use of dehydroepiandrosterone derivatives for the preparation of a pharmaceutical preparation and pharmaceutical composition containing the derivative
US5846963A (en) 1995-06-07 1998-12-08 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
US5387583A (en) * 1993-04-20 1995-02-07 Loria; Roger M. Compositions containing corticosteroids or analogues thereof and corticosteroid buffering effective amounts of 5-androstene 3B, 17B or 5-androstene 3B, 7B, 17B triol or analogues thereof
US5554601A (en) 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US5877169A (en) 1993-11-05 1999-03-02 University Of Florida Research Foundation, Inc. Methods of treatment of ischemic damage
US5976850A (en) * 1994-10-19 1999-11-02 University Of Edinburgh Hippocampus-associated proteins; DNA sequences coding therefor and uses thereof
US5556847A (en) * 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
CA2223996A1 (en) 1995-06-06 1996-12-19 Cocensys, Inc. Neuroactive steroids of the androstane and pregnane series
EP0840612A1 (en) 1995-07-24 1998-05-13 Trustees Of Boston University Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
GB2317826B (en) * 1995-08-29 1999-12-15 Univ Edinburgh Regulation of intracellular glucocorticoid concentrations
US5985242A (en) 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
CA2250874A1 (en) * 1996-04-09 1997-10-16 Btg International Limited Use of 7 alpha-substituted steroids to treat neuropsychiatric, immune or endocrine disorders
DK0929574T3 (da) 1996-08-27 2005-10-31 Praecis Pharm Inc Modulatorer af beta-amyloidpeptidaggregering, som omfatter D-aminosyrer
FR2760362B1 (fr) * 1997-03-10 2000-08-11 Vitasterol Utilisation cosmetique ou dermatologique de steroides 7-hydroxyles
WO1998043647A1 (en) * 1997-03-28 1998-10-08 Massachusetts Institute Of Technology, Inc. Regulation of amyloid precursor protein (app) expression by estrogenic compounds
GB9708716D0 (en) * 1997-04-29 1997-06-18 Imperial College Chronic heart failure
US6544972B1 (en) * 1997-09-25 2003-04-08 Regents Of The University Of Minnesota Methods of limiting apoptosis of cells
AU1387399A (en) 1997-11-10 1999-05-31 Vyrex Corporation Probucol esters and uses thereof
US6172088B1 (en) * 1997-11-24 2001-01-09 University Of Florida Research Foundation, Inc. Testosterone compounds and use for the protection of neurons
GB9726569D0 (en) 1997-12-16 1998-02-11 Univ Southampton Neuroprotective agents
WO1999052532A1 (en) * 1998-04-14 1999-10-21 Pharmadigm, Inc. Method for reducing central nervous system impairment
FR2786102B1 (fr) * 1998-11-20 2001-02-16 Monique Vincens Utilisation de sulfate de dehydroepiandrosterone pour augmenter le nombre de recepteurs nmda chez un mammifere
US20030083231A1 (en) 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
JP2003513102A (ja) 1999-11-02 2003-04-08 シエーリング アクチエンゲゼルシャフト 選択的な作用を有するエストロゲンとしての１８−ノル−ステロイド
GB0003524D0 (en) 2000-02-15 2000-04-05 Btg Int Ltd Cytoprotective steroids (II)
GB2363984A (en) 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
EP1557166A1 (en) * 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders

Also Published As

Publication number Publication date
EP1294382A1 (en) 2003-03-26
HK1052300B (en) 2009-01-30
HUP0301134A2 (hu) 2003-08-28
CA2414584A1 (en) 2002-01-03
ZA200300085B (en) 2004-04-21
RU2307654C2 (ru) 2007-10-10
NO20026243D0 (no) 2002-12-27
ES2310182T3 (es) 2009-01-01
KR100786284B1 (ko) 2007-12-18
PT1294382E (pt) 2008-10-21
HU227152B1 (en) 2010-08-30
PL359108A1 (en) 2004-08-23
US7718639B2 (en) 2010-05-18
KR20030034113A (ko) 2003-05-01
ATE401897T1 (de) 2008-08-15
CN1440290A (zh) 2003-09-03
NO327959B1 (no) 2009-10-26
CA2414584C (en) 2009-10-27
JP2004501196A (ja) 2004-01-15
HUP0301134A3 (en) 2006-06-28
IL153541A (en) 2008-03-20
DK1294382T3 (da) 2008-11-24
DE60134979D1 (de) 2008-09-04
AU2001267709B2 (en) 2005-07-28
WO2002000225A1 (en) 2002-01-03
GB0016022D0 (en) 2000-08-23
JP4942905B2 (ja) 2012-05-30
CZ200377A3 (cs) 2003-06-18
CN100459980C (zh) 2009-02-11
EP1294382B1 (en) 2008-07-23
AU6770901A (en) 2002-01-08
GB2363983A (en) 2002-01-16
US20100173883A1 (en) 2010-07-08
CZ299676B6 (cs) 2008-10-15
IL153541A0 (en) 2003-07-06
NO20026243L (no) 2003-02-27
PL200699B1 (pl) 2009-01-30
CY1108773T1 (el) 2014-04-09
HK1052300A1 (en) 2003-09-11
US20030166626A1 (en) 2003-09-04
SI1294382T1 (sl) 2009-02-28

Similar Documents

Publication Publication Date Title
CA2260037A1 (en) Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
DE60142236D1 (de) Substituierte 5-alkinyl-pyrimidine mit neurotropher wirkung
NL300205I1 (nl) N-enentiomeer van N-propargyl-1-aminoindaan voor de behandeling van verschillende ziekten, en mesylaat, esylaat en sulfaat daarvan.
ATE294774T1 (de) Aminoadamantan-derivate als therapeutische mittel
EA200500699A1 (ru) Комбинированная терапия с использованием производных 1- аминоциклогексана и ингибиторов ацетилхолинэстеразы
EP1979324A4 (en) IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF COGNITIVE DISORDER, MORBUS ALZHEIMER, NEURODEGENERATION AND DEMENTIA.
PH31394A (en) Certain Ä,2,5-thiadiazol-4-ylÜ-1-azabicyclo Ä3,2,1Üoctane derivaives and their pharmaceutical uses.
NO20063276L (no) Anvendelse av rotigotin til behandling eller forhindring av dopaminergt nevrontap
MXPA02011373A (es) Derivados de triazol.
WO2004071431A3 (en) Method and composition for treating neurodegenerative disorders
AU2003220096A8 (en) Methods for alzheimer's disease treatment and cognitive enhancement
HU9602281D0 (en) Novel opioid peptides for the treatment of pain and use thereof
ES2173111T3 (es) Uso de fenserina para la preparacion de medicamentos para el tratamiento de desordenes cognoscitivos.
RU2003102437A (ru) 7-гидроксиэпиандростерон, обладающий нейропротективной активностью
EP2277528A3 (en) Use of VEGF and homologues to treat neuron disorders
RU93030389A (ru) Средство, восстанавливающее функцию сетчатой оболочки глаза
BRPI0408601A (pt) compostos com ação nootrópica, sua preparação, composições farmacêuticas os contendo, e seu uso
SI1173179T1 (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent major depressive disorders
WO2007106862A3 (en) The use of statins to stimulate neurogenesis
EP1297849A4 (en) CURATIVE AGENT FOR OPTICAL AND SIMILAR NERVE DISEASES
BR0113201A (pt) processo para tratar distúrbios neurodegenerativos da retina e da cabeça do nervo óptico
CA2388728A1 (en) Use of beta-adrenoceptor antagonists for the manufacture of a medicament for the treatment of disorders of the outer retina
WO2002076437A3 (en) Methods for treating neurodegenerative diseases including alzheimer's
WO2001010428A3 (en) Use of n-methyl bases of ethanolamine for prevention of cell death induced by oxidative stress
ZA200804105B (en) Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, Alzheimer's Disease, neurodegeneration and dementia

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20130630